ClinConnect ClinConnect Logo
Search / Trial NCT00999102

Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life

Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Oct 20, 2009

Trial Information

Current as of June 03, 2025

Completed

Keywords

Hypertension Beta Blockers Metoprolol Blood Pressure, High Antihypertensive Agents Vascular Resistance Adrenergic Beta Receptor Blockaders Beta Adrenergic Blockers Beta Adrenergic Blocking Agents Beta Adrenergic Receptor Blockaders Beta Blockers, Adrenergic Bystolic Nebivolol Nebivololum Nebivololum [Latin] R65,824 Beloc Zok H 93/26 Succinate Metoprolol Succinate Seloken Zoc Selozok Spesicor Dos Toprol Xl Toprol Xl Unii Th25 Pd4 Ccb

ClinConnect Summary

* Hypothesis: the beta-blocker nebivolol is associated with less fatigue than metoprolol, the most widely-prescribed beta-blocker
* Methods: a double-blinded crossover trial comparing nebivolol with metoprolol. Experimental procedures: Subjects will undergo electrocardiogram and routine blood testing, unless such tests have been performed within 6 months and are available for review. Subjects entered into the study will receive each of the two study drugs for 8 weeks. Metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks. For nebivolol, dosag...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals who are taking, or are about to begin taking, a beta-blocker, and who have the approved indication of hypertension
  • Exclusion Criteria:
  • Orthopedic ailments that would interfere with performance of treadmill testing
  • Stroke or heart attack within the previous 1 year
  • Symptomatic coronary disease within the past year (angina, shortness of breath)
  • Clinically significant pulmonary disease (e.g. emphysema or asthma).
  • Poorly controlled hypertension (blood pressure above 160 systolic or 100 diastolic)
  • Patients with contra-indications to taking a beta-blocker (asthma or bradyarrhythmia)
  • History of tachyarrhythmia (abnormal rapid heart rate)

About Weill Medical College Of Cornell University

Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Samuel J Mann, MD

Principal Investigator

Weill Medical College of Cornell University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials